Moberg Pharma resolves on a rights issue of approximately SEK 100 million
STOCKHOLM, 28 June 2023. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or the "Company”) has today resolved to carry out a new issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 100 million before transaction costs. The Rights Issue is conditional upon approval at an extraordinary general meeting (the "Extraordinary General Meeting"). The net proceeds will mainly be used for clinical and regulatory activities for MOB-015 and preparations ahead of launch. The background